HMG

Where HCG reproduces only the LH pathway, HMG covers both gonadotropins. Human menopausal gonadotropin, also called menotropin, was originally obtained from the urine of postmenopausal women; today highly purified and recombinant forms exist alongside it. Its hallmark is a defined ratio of FSH to LH activity, typically 1:1.

The two components act on different cells:

• FSH activity drives follicle maturation in the ovary and Sertoli cell function in the testis in preclinical models.
• LH activity stimulates steroid synthesis in theca and Leydig cells.

Because germ cell maturation and steroid hormone production depend on both signals, a preparation with only one component gives an incomplete picture of the reproductive axis. That is where HMG fits into research. Its half-life lies in the range of several hours.

What the clinical literature contributes:

• A 2011 Cochrane analysis pooled 9606 couples from 42 trials to compare recombinant FSH with urinary gonadotropins such as HMG; the live birth rate did not differ significantly between the two.
• In 75 men with gonadotropin deficiency, sperm first showed up after a median 7.1 months of gonadotropin treatment and 38 became fathers; a larger testicular volume predicted a faster response.
• A historical review from 2004 traces the path from the first pituitary and urine extracts to today's preparations.

HMG is listed here strictly as a research compound. What you read places the evidence in context and does not replace professional information.

With two gonadotropin activities, HMG intervenes more broadly in the reproductive hormone axis than a single-component product:

• Axis shift: combined stimulation of germ cell maturation and steroid synthesis can alter the body's own regulation in preclinical models.
• Oestrogenic effects: as with other gonadotropins, increased steroid production can lead to more oestradiol, with water retention as a known consequence.
• Injection site: redness, pressure or a brief irritation are common, particularly with subcutaneous dosing.
• Long-term data: for extended use outside clinical fertility studies there are no robust human data; the assessment rests on those studies and on animal models.

This summary is no substitute for medical advice.

• Historical perspectives in gonadotrophin therapy - 2004 retrospective on the development of gonadotropin preparations.
• Recombinant versus urinary gonadotrophin for ovarian stimulation in assisted reproductive technology cycles - 2011 Cochrane analysis of 42 trials and 9606 couples.
• Induction of spermatogenesis and fertility during gonadotropin treatment of gonadotropin-deficient infertile men: predictors of fertility outcome - 2009 analysis of 75 men with gonadotropin deficiency.